IMM Immupharma Plc

TIDMIMM

RNS Number : 5094Z

Immupharma PLC

24 May 2021

24 May 2021

ImmuPharma PLC

("ImmuPharma" or the "Company")

DIRECTOR RETIREMENT

ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that Dr Robert Zimmer, President & Chief Science Officer has confirmed to the Company that he will not be seeking re-election at the forthcoming Annual General Meeting scheduled for 28 June 2021 and will be retiring from ImmuPharma PLC and leaving the Board with effect from then.

The Board would like to express its gratitude to Dr Zimmer for his 16 years of service and wishes him well for the future.

As a substantial shareholder in ImmuPharma and to demonstrate his continued support of the Company, Dr Zimmer has entered into a lock-in agreement, to not dispose of shares in which he has an interest, for a period of three years or, if earlier than three years, the date of the reporting by the Company of the preliminary results of the next Phase 3 clinical trial of Lupuzor(TM) .

Commenting on the announcement, Dimitri Dimitriou, CEO of ImmuPharma said : "Having co-founded ImmuPharma in 2005, Robert has been a driving force in the business for many years, both scientifically and through our strategic collaborations, in particular the longstanding relationship with the CNRS * . On behalf of the Board and all our colleagues, I thank him for his invaluable and unique contribution."

Dr Robert Zimmer, added: "I have taken great pride at being at the helm of ImmuPharma, working with such highly committed and exceptionally talented colleagues. Whilst my retirement from the Company will allow me to focus on the many endeavours now afforded to me, as a major shareholder in ImmuPharma, I remain fully supportive of the Company, its diverse pipeline and technology but most specifically, the long-term success of Lupuzor(TM). As such, I have every confidence that Lupuzor(TM) has the potential of becoming a first line treatment for the many lupus patient sufferers around the world."

*CNRS : Centre National de la Recherche Scientifique

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. on publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 
 For further information please contact: 
   ImmuPharma PLC ( www.immupharma.com ) 
    Tim McCarthy, Chairman                        + 44 (0) 207 152 4080 
   Dimitri Dimitriou, Chief Executive Officer 
   Lisa Baderoon, Head of Investor Relations      + 44 (0) 7721 413496 
   SPARK Advisory Partners Limited (NOMAD) 
    Neil Baldwin 
 
    Stanford Capital Partners (Joint Broker)      +44 (0) 203 36 8 3550 
    Patrick Claridge 
    John Howes 
    Bob Pountney                                   +44 (0) 203 815 8880 
 
    SI Capital (Joint Broker) 
    Nick Emerson                                   +44 (0) 1483 413500 
   4Reliance (Euronext Growth Listing Sponsor)    +32 (0) 2 747 02 60 
    Jean-Charles Snoy 
 
    Degroof Petercam (Liquidity Provider)          +32 (0) 2 287 95 34 
    Erik De Clippel 
 
    Backstage Communication 
    Olivier Duquaine                               +32 (0) 477 504 784 
    Gunther De Backer                              +32 (0) 475 903 909 
 

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor(TM), is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor(TM) to fund a new international Phase 3 trial for Lupuzor(TM) and commercialise in the US.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOASELFWDEFSEDI

(END) Dow Jones Newswires

May 24, 2021 02:00 ET (06:00 GMT)

Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024